CN207912919U - A kind of multivitamin tablet capsule - Google Patents
A kind of multivitamin tablet capsule Download PDFInfo
- Publication number
- CN207912919U CN207912919U CN201621459935.7U CN201621459935U CN207912919U CN 207912919 U CN207912919 U CN 207912919U CN 201621459935 U CN201621459935 U CN 201621459935U CN 207912919 U CN207912919 U CN 207912919U
- Authority
- CN
- China
- Prior art keywords
- vitamin
- capsule
- tablet
- sustained release
- piece
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The utility model is related to preparation technique field, more particularly to a kind of multivitamin tablet capsule.The multivitamin tablet includes the multivitamin tablet in capsule and capsule, capsule includes capsule body 1 and capsule cap 2, multivitamin tablet in capsule includes B family vitamin piece 3, VITAMIN C TABLET 4 and mcg vitamin piece 5,5 random alignment of B family vitamin piece 3, VITAMIN C TABLET 4 and mcg vitamin piece.The utility model prepares B family vitamin piece, VITAMIN C TABLET and mcg vitamin piece respectively, is subsequently filled capsule, can effectively improve the stability of each vitamin.
Description
Technical field
The utility model is related to preparation technique field, more particularly to a kind of multivitamin tablet capsule.
Background technology
Vitamin is a kind of nutriment that is required in diet, can meeting body needs on a small quantity.Although dimension
Raw element molecule is small, quantity is little but most important to body, is generally divided into liposoluble vitamin and water soluble vitamin.Liposoluble
Property vitamin include vitamin A. D. E, K and its derivative, be to maintain body normal growth, development, metabolism and organism physiology work(
Substance necessary to energy.
Vitamin A is also known as retinol, only exists in animal food, has and maintains vision, reproduction, cell development
Etc. physiological functions, but it is excessive hepatotoxicity can be caused to act on, visual impairment, pregnant woman produce malformation fetus.Vitamin E is also known as given birth to
Phenol has the function of anti-oxidant, anti-aging, protection blood vessel, promotes fertility.Vitamin D is sterol analog derivative, can promote calcium
It is deposited in bone, has anti-rachitic effect.If shortage or excess intake, will cause metabolic imbalance, will produce when serious
Lack disease or even causing death.Water soluble vitamin includes B family vitamin and vitamin C etc..Vitamin C also known as anti-bad
Hematic acid is a kind of water soluble vitamin, unstable chemcial property, the oxidizable degradation under light, heat, oxygen, alkaline ring.Vitamin C
With enhancing immunity of organisms, improve heart function, reducing blood lipid, antithrombotic, the pharmacological actions such as anticancer.Oral vitamin C is usual
There is a small amount of absorption in mucous membrane of mouth and stomach, mainly (duodenum and upper-jejunum) is absorbed above small intestine.Its absorption process
It is the process of an active transport, absorbability is related with the quantity of carrier.When intake is in 30-180mg, absorptivity is reachable
70%-90%；However when intake is 1500mg, absorptivity drops to 50%；When intake reaches 6000mg, absorptivity is then
Only 16%.Therefore when clinically needing large dose oral administration vitamin C, need to be administered daily 3-4 times, frequent and large dosage of gives
Medicine can lead to patient's poor compliance, easily occur missing phenomenon, and instantaneous larger dose take can cause vitamin C without
Method is absorbed, and optimum therapeuticing effect is not only not achieved, but also can cause the prodigious waste of vitamin C.
B family vitamin is one kind important in water soluble vitamin, and many of is the component part of the prothetic group of enzyme and enzyme.
When lacking B family vitamin in human body, the generation of a variety of diseases can be caused, and human body itself can not synthesize these chemical combination
Object, it is necessary to by food chain or take Cernevit-12 and give and supplement.It is multiple with the raising that people require quality of the life
The appearance for closing vitamin preparation and high-grade nutriment produces extensive concern to B family vitamin in food or in drug.Dimension life
Plain B1(VB1), vitamin B2 (VB2) it is required nutritional factors in people's life, being some has adjusting and control new old generation
It apologizes for having done sth. wrong the bioactive substance of Cheng Zuoyong.VB1There is a substantial connection with glycometabolism, when shortage can make third in blood, urine and nerve fiber
Ketone acid content increases and obtains athlete's foot.VB2Physiological function be to participate in oxidation as coenzyme, when shortage, can make skin, eye
Eyeball and nervous system injury.Vitamin B3(niacin) can excessively cause hyperglycemia, hepatotoxicity effect.
Currently, water soluble vitamin and liposoluble vitamin are generally separately formed vitamin preparation by multi-vitamins, when
Clinically or in life when large dose oral administration multivitamin tablet, the compliance of patient is poor, often occurs missing existing
As.Disclosure/notification number be CN105267236A disclose a kind of multi-vitamins soft capsule, by vitamin A, vitamine D3,
Vitamin E, vitamin B1, vitamin B2, vitamin B6, niacin, pantothenic acid, folic acid, vitamin C, zinc, selenium and iron are by a certain percentage
It is mixed and made into soft capsule, but the study show that various vitamins, which are mixed, will reduce the stability of certain vitamins.How
It develops a kind of multivitamin tablet of stabilization and receives people's concern always.
Utility model content
In view of this, the utility model provides a kind of multivitamin tablet capsule.The multivitamin tablet capsule can have
Effect maintains the stability of various vitamins.
In order to realize that above-mentioned purpose of utility model, the utility model provide following technical scheme：
The utility model provides a kind of multivitamin tablet capsule, including the multivitamin tablet in capsule and capsule,
Capsule includes capsule body 1 and capsule cap 2, and the multivitamin tablet in capsule includes B family vitamin piece 3, VITAMIN C TABLET 4 and micro-
Measure multivitamin 5,5 random alignment of B family vitamin piece 3, VITAMIN C TABLET 4 and mcg vitamin piece.
Preferably, multivitamin tablet is coating multivitamin tablet.
Preferably, the shape of multivitamin tablet is cylinder, sphere or multi-face solid structure.
Preferably, the gap in multivitamin tablet capsule is filled by auxiliary material.
Preferably, auxiliary material is hypromellose, microcrystalline cellulose, maltodextrin, pregelatinized starch, different malt ketone
Sugar alcohol, starch or dextrin.
Preferably, B family vitamin piece is B family vitamin sustained release tablets.
Preferably, VITAMIN C TABLET is vitamin C sustained release tablets.
Preferably, one kind in the model of capsule 0 to 5.
Preferably, one kind in the model of capsule 0 to 3.
Preferably, B family vitamin sustained release tablets include B family vitamin, sustained-release matrix material and lubricant.
Preferably, B family vitamin is selected from VB in B family vitamin piece1、VB2、VB3、VB5、VB6、 VB7、VB12In one kind
Or it is several.
Preferably, per in 180mg B family vitamin sustained release tablets, each component dosage is：VB10~4.8mg, VB20~
4.8mg, VB30~40.0mg, VB50~12.0mg, VB60~4.8mg, VB710~45.0mg, VB120~4.8mg.
Preferably, vitamin C sustained release tablets include vitamin C, sustained-release matrix material, antioxidant, glidant and lubricant.
Preferably, per in 180mg VITAMIN C TABLETs, ascorbic dosage is 1~150mg.
Preferably, per in 180mg VITAMIN C TABLETs, ascorbic dosage is 50~150mg.
Preferably, mcg vitamin piece includes mcg vitamin, filler, disintegrant, glidant and lubricant.
Preferably, mcg vitamin is selected from VB7、VB12、VB9(folic acid), vitamin A, vitamin D3, natural VE
One or more of acetate.
Preferably, per in 180mg mcg vitamin pieces, mcg vitamin each group component is：VB70.1~0.9mg,
VB120.001~0.0048mg, 0.1~1.0mg of folic acid, 0.1~1.0mg of vitamin A, vitamin D31~10mg, it is natural to tie up
10~40mg of raw element E acetates.
Preferably, sustained-release matrix material is selected from hypromellose, xanthans, seaweed in B family vitamin sustained release tablets
One or more of sour sodium, carbomer, sodium carboxymethylcellulose, A Kabai glue, xanthans or carragheen.
Preferably, the mass percentage of sustained-release matrix material is 30%~60% in B family vitamin sustained release tablets.
Preferably, hypromellose is K100LV, K4M, K15M or K100M.
Preferably, the mass percentage of sustained-release matrix material is 40%~50% in B family vitamin sustained release tablets.
Preferably, sustained-release matrix material is hypromellose K4M and carboxymethyl cellulose in B family vitamin sustained release tablets
The mass ratio of sodium, hypromellose K4M and sodium carboxymethylcellulose is (1:1)~(10:1).
It is highly preferred that the mass ratio of hypromellose K4M and sodium carboxymethylcellulose is (4.3：1)~(9.5：
1)。
Preferably, sustained-release matrix material is hypromellose K4M and carbomer, hydroxypropyl in B family vitamin sustained release tablets
The mass ratio of methylcellulose K4M and carbomer is (1:1)~(10:1).
It is highly preferred that the mass ratio of hypromellose K4M and carbomer is (4.3：1)~(9.5： 1).
Lubricant is selected from one or more of magnesium stearate, polyethylene glycol or talcum powder, moistens in B family vitamin sustained release tablets
The mass percentage of lubrication prescription is 0.001%~1%.
Preferably, sustained-release matrix material is selected from hypromellose, sodium alginate, card wave in vitamin C sustained release tablets
One or more of nurse, sodium carboxymethylcellulose, carragheen, xanthans or Arabic gum.
Preferably, the mass percentage of sustained-release matrix material is 30%~60% in vitamin C sustained release tablets.
It is highly preferred that the mass percentage of sustained-release matrix material is 30%~50% in vitamin C sustained release tablets.
Preferably, hypromellose is K100LV, K4M, K15M or K100M.
Preferably, hypromellose is hypromellose K100M and sodium carboxymethylcellulose, or is hydroxypropyl
Methylcellulose K100M and carbomer.
Preferably, antioxidant is selected from thiocarbamide, thio threitol, sodium sulfite, niter cake, citric acid, tartaric acid, apple
One or more of tartaric acid or boric acid.
Preferably, in vitamin C sustained release tablets antioxidant mass percentage be 0.1%~2%, preferably 0.5%~
1.5%.
Preferably, glidant is colloidal silicon dioxide and/or silica.
Preferably, in vitamin C sustained release tablets glidant mass percentage be 0.1%~2%, preferably 0.1%~
1%.
Preferably, lubricant is selected from one or more of magnesium stearate, polyethylene glycol or talcum powder.
Preferably, the mass percentage of lubricant is 0.1%~2% in vitamin C sustained release tablets.
Preferably, the mass percentage of lubricant is 0.1%~1% in vitamin C sustained release tablets.
Preferably, in mcg vitamin piece filler be lactose, microcrystalline cellulose, starch, mannitol, calcium phosphate or
One or more of calcium sulfate.
Preferably, filler is lactose and microcrystalline cellulose.
Preferably, the mass percentage of filler is 10%~60% in mcg vitamin piece.
Preferably, the mass percentage of filler is 20%~50% in mcg vitamin piece.
Disintegrant is dried starch, carboxyrnethyl starch sodium, croscarmellose sodium, crospovidone or low-substituted hydroxypropyl first
One or more of base cellulose.
Preferably, disintegrant is carboxyrnethyl starch sodium.
Preferably, the mass percentage of disintegrant is 1%~20% in mcg vitamin piece.
Preferably, the mass percentage of disintegrant is 1%~15% in mcg vitamin piece.
Preferably, glidant is superfine silica gel powder and/or SiO2。
Preferably, the mass percentage of glidant is 0.001%~1% in mcg vitamin piece.
Preferably, in mcg vitamin piece one kind in magnesium stearate, polyethylene glycol or talcum powder of lubricant or
It is several.
Preferably, the mass percentage of lubricant is 0.001%~1% in mcg vitamin piece.
In embodiment provided by the utility model, B family vitamin sustained release tablets, vitamin C sustained release tablets and mcg vitamin
3 tablets of piece are prepared by the formulation method of powder vertical compression and film coating.The concrete technology of preparation：Each supplementary material is crossed 60
It is uniformly mixed after~100 mesh screens, it is spare；Then the lubricant of recipe quantity is added, is uniformly mixed, tabletting；Outside last sustained release tablets
Layer packet moisture protection clothing.
Preferably, B family vitamin sustained release tablets further include coating material；Vitamin C sustained release tablets further include coating material；It is micro-
It further includes coating material to measure multivitamin.
Coating powder：Hydroxypropyl methyl cellulose, Ponceau 4R aluminum lake, Sunset yellow aluminum lake, talcum powder, gathers titanium dioxide
The combination not of the same race such as polysaccharide, glyceryl triacetate and tartrazine aluminum lake；B family vitamin sustained release tablets packet yellow film clothing.
The utility model provides a kind of multivitamin tablet capsule.The multivitamin tablet includes in capsule and capsule
Multivitamin tablet, capsule include capsule body 1 and capsule cap 2, and the multivitamin tablet in capsule includes B family vitamin piece 3, dimension
Raw element C pieces 4 and mcg vitamin piece 5,5 random alignment of B family vitamin piece 3, VITAMIN C TABLET 4 and mcg vitamin piece.This practicality
It is novel that at least there is one of following advantage：
1, the utility model prepares B family vitamin piece, VITAMIN C TABLET and mcg vitamin piece respectively, is subsequently filled capsule,
The stability of each vitamin can be effectively improved；
2, the multivitamin capsule that prepared by the utility model is convenient to take, and compliance is good；
3, the vitamin slow-releasing piece capsule slow release effect that prepared by the utility model is good；
4, after the utility model fills in the gap in multivitamin tablet capsule with auxiliary material, intracapsular of fixing glue can be played
The purpose of agent reduces the abrasion between tablet, avoids between tablet due to being ruptured caused by collision；
5, the multivitamin preparation process that prepared by the utility model is convenient and efficient, and drugloading rate is high；Tablet fills capsule designs,
Small and exquisite novelty, it is easy to carry, it is conducive to industrialized production.
Description of the drawings
Fig. 1 shows B family vitamin sustained release tablets release profiles in embodiment 1；
Fig. 2 shows B family vitamin sustained release tablets release profiles in embodiment 2；
Fig. 3 shows B family vitamin sustained release tablets release profiles in comparative example 1；
Fig. 4 shows in comparative example 1 VB9 stability in B family vitamin sustained release tablets；
Fig. 5 shows the stability of other VB in B family vitamin sustained release tablets in comparative example 1；
Fig. 6 shows vitamin C sustained release tablets release profiles in embodiment 3；
Fig. 7 shows vitamin C sustained release tablets Acceleration study sample release profiles in embodiment 3；
Fig. 8 shows vitamin C sustained release tablets release profiles in embodiment 4；
Fig. 9 shows in embodiment 5 VB9 stability in mcg vitamin piece；
Figure 10 shows the mode of appearance structure chart of multivitamin tablet capsule；Wherein, 1 shows capsule body, and 2 show capsule cap, and 3 show B
Family vitamin piece, 4 show VITAMIN C TABLET, and 5 show mcg vitamin piece.
Specific implementation mode
The utility model discloses a kind of multivitamin tablet capsule, those skilled in the art can use for reference present disclosure,
It is suitably modified technological parameter realization.In particular, it should be pointed out that all similar substitutions and modifications carry out those skilled in the art
Say it is it will be apparent that they are considered as being included in the utility model.The method of the utility model and application by compared with
Good embodiment is described, related personnel obviously can not depart from the utility model content, in spirit and scope to this paper institutes
The methods and applications stated are modified or suitably change and combine, to realize and apply the utility model technology.
Term is explained：
As used herein, term " multi-vitamins sustained-release matrix tablets ", " multi-vitamins sustained-release gel matrix tablet ", " multiple
Close vitamin slow-releasing piece " it is used interchangeably, it is to become gel skeleton preparation using multi-vitamins and gel skeleton mixed pressuring plate,
It encounters water and forms certain gel form, a kind of sustained-release preparation of the mechanism formation of Drug controlled release.
As used herein, term " VB " refers to B races multi-vitamins.
As used herein, term " VC " refers to vitamin C.
As used herein, term " VADE " refers to multi-vitamins A, multi-vitamins D, multi-vitamins E.
Each B family vitamin is write a Chinese character in simplified form as follows：
| Thiamin mononitrate： | VB1 | Puridoxine hydrochloride： | VB6 |
| Riboflavin： | VB2 | Biotin： | VB7 |
| Niacinamide： | VB3 | Folic acid： | VB9 |
| Calcium pantothenate： | VB5 | Cobalamin： | VB12 |
In the examples below, vitamin A is vitamin A powder (325000IU), and vitamine D3 is vitamin d3 powder
(100000IU/g, 2.5 ‰), and natural VE acetate is natural VE acetate powder (50%).
Raw materials used or auxiliary material is available on the market in multi-vitamins sustained release tablets capsule provided by the utility model.
With reference to embodiment, the utility model is expanded on further：
The preparation of 1 B family vitamin sustained release tablets of embodiment
(1) formula of B family vitamin sustained release tablets is as follows：
The formula of 1 B family vitamin sustained release tablets of table
(2) preparation method：Each supplementary material is uniformly mixed, it is spare.It is eventually adding the magnesium stearate of recipe quantity, mixing is equal
It is even, tabletting.Specially：
First uniformly (material is 1.) by VB1, VB2, VB5, VB6 and VB12 hand mix；1. material is mixed with VB3, VB7 equal
Even (material is 2.)；2. material is uniformly mixed with HPMC (K4M SR/K15M SR), CMCNa with three-dimensional mixer, be eventually adding hard
Fatty acid magnesium mixes.
Tabletting parameter：Diameter 6mm, piece weight 175-185mg
(3) drug release determination method：
Chromatographic condition：Chromatographic column is Agilent ZORBAX Plus C18 chromatographic columns 2.1 × 100mm, 3.5 μm)；Column
Temperature：25℃；Mobile phase is 10mM ammonium formates-acetonitrile；Flow velocity：0.20 mL/min；Sample size：1μL；
Mass Spectrometry Conditions：Dry temperature degree and flow velocity are 300 DEG C and 8L/min；Sheath temperature degree and flow velocity are 350 DEG C and 8L/
min；Atomization gas pressure is 35psi；Capillary voltage is 3500V；Spray nozzle voltage is 500V；△ EMV are 200eV；Detect ion
As shown in the table：
The testing result of 2 B family vitamin sustained release tablets of table
| VB | m/z | T(min) |
| VB1 | 265.1>122 | 1.18 |
| VB2 | 377.1>243 | 3.71 |
| VB3 | 123.1>80.1 | 1.4 |
| VB5 | 220.1>90 | 1.8 |
| VB6 | 170.1>152 | 1.34 |
| VB7 | 245.1>227 | 4.70 |
| VB12 | 678.3>147 | / |
Drug release determination device：Chinese Pharmacopoeia paddle method；
Leaching condition：Medium is 1000mL deionized waters, rotating speed 100rpm, 37 DEG C of temperature；
It is measured by sampling：5mL, and fluid infusion 5mL are sampled in 0.5,1,2,4,6,8,10 and 12h, dilutes 10 times as dissolution sample
Product are measured with LC-MS/MS.Release result such as Fig. 1.
The result shows that a preferable slow release effect is all presented in each B family vitamin.The prescription of selection example 1, into
After the detection of row release, according to its release that is averaged (being shown in Table 2), using Zero order release, first-order release, Higuchi equations,
Ritger-Peppas equations and Hixson-Crowell equations are fitted respectively, determine fit equation, and it is quasi- to calculate each model
Close equation coefficient R value, determine the best fit model of sustained release tablets release in vitro, according to fitting result to release Mechanisms into
Row Primary Study and analysis.The result shows that：B family vitamin sustained release tablets have significant slow release effect, wherein in compound VB sustained release tablets,
VB2 is in Zero order release, and VB1, VB3, VB5 and VB6 are in first-order release, and VB7 is discharged in Higchi.
(4) vitamin B sustained release tablets accelerated stability is tested
By vitamin B sustained release tablets temperature be 40 DEG C, humidity be 75% stability experiment case in carry out accelerated stability
Experiment is investigated, and under the conditions of the different acceleration time, the similitude f2 values of vitamin B sustained release tablets release profiles are all more than 50, content without
Notable difference.Vitamin B sustained release tablets in the utility model have good stability.
The preparation of 2 B family vitamin sustained release tablets of embodiment
(1) formula of B family vitamin sustained release tablets is as follows：
The formula of 3 B family vitamin sustained release tablets of table
(2) preparation method：Each supplementary material is uniformly mixed, it is spare.It is eventually adding the magnesium stearate of recipe quantity, mixing is equal
It is even, tabletting.Specially：
First uniformly (material is 1.) by VB1, VB2, VB5 and VB6 hand mix；1. material is uniformly mixed (material with VB3
②)；2. material is uniformly mixed with HPMC (K4M SR/K15M SR), CMCNa with three-dimensional mixer, it is mixed to be eventually adding magnesium stearate
It closes.
Tabletting parameter：Diameter 6mm, piece weight 175-185mg.
(3) drug release determination method is the same as embodiment 1, release result such as Fig. 2.
(4) vitamin B sustained release tablets accelerated stability is tested
By vitamin B sustained release tablets temperature be 40 DEG C, humidity be 75% stability experiment case in carry out accelerated stability
Experiment is investigated, and under the conditions of the different acceleration time, the similitude f2 values of vitamin B sustained release tablets release profiles are all more than 50, content without
Notable difference.Vitamin B sustained release tablets in the utility model have good stability.
1 B family vitamin sustained release tablets of comparative example
(1) formula of B family vitamin sustained release tablets is as follows：
The formula of 4 B family vitamin sustained release tablets of table
(2) preparation method：Each supplementary material is uniformly mixed, it is spare.It is eventually adding the magnesium stearate of recipe quantity, mixing is equal
It is even, tabletting.Specially：
First uniformly (material is 1.) by VB1, VB2, VB5, VB6, VB9 and VB12 hand mix；1. material is mixed with VB3, VB7
It closes uniformly (material is 2.)；2. material is uniformly mixed with HPMC (K4M SR/K15M SR), CMCNa with three-dimensional mixer, finally add
Enter magnesium stearate mixing.
Tabletting parameter：Diameter 6mm, piece weight 175-185mg.
(3) B family vitamin release methodology：LC-MS/MS, with embodiment 1.
Specific experiment result is shown in Fig. 3.
(4) Detection of Stability
Detection method：Each VB prepares certain density solution and mixes (mixed liquor respectively respectively in VB sustained release tablets
Middle VB1,2.40ng/mL；VB2,2.40ng/mL；VB3,20.00ng/mL；VB5,6.00ng/mL；VB6,2.40ng/mL；
VB7,45.00ng/mL；VB9,0.40ng/mL；VB12,3.20ng/mL), different vitamin groups are investigated under conditions of 37 DEG C
Stability between conjunction.As a result see Fig. 4,5.
Test result：In stability study in the assembled scheme of vitamin slow-releasing piece, each VB difference in VB sustained release tablets
It prepares certain density solution to mix respectively, the stabilization between different vitamin combinations is investigated under conditions of 37 DEG C
Property.Wherein, by taking VB9 as an example, each VB and auxiliary material all have an impact VB9 stability in VB sustained release tablets, steady between other B family vitamins
It is qualitative good；VB9 has little effect other compositions.Therefore, it needs to give birth to VB9 and other B races dimension in the present invention
Element is prepared separately tablet, to improve the stability of VB9.
3 vitamin C sustained-release tablet recipe of embodiment
(1) formula of vitamin C sustained release tablets is as follows：
The formula of 5 vitamin C sustained release tablets of table
| Ingredient | Every dosage/mg | Percentage/% |
| VC (60 mesh) | 100.0 | 55.6 |
| HPMC(K100M) | 40.2 | 22.3 |
| Chitosan (CS) | 18.0 | 10.0 |
| Carbomer | 18.0 | 10.0 |
| Citric acid | 2.0 | 1.1 |
| Superfine silica gel powder | 0.9 | 0.5 |
| Magnesium stearate | 0.9 | 0.5 |
| Piece weight | 180 | / |
(2) preparation method：Formulation and technology is powder vertical compression.Specially：
HPMC (K100M), chitosan, carbomer, citric acid use after sieving with 100 mesh sieve in prescription.
The VC, CS, carbomer, superfine silica gel powder of recipe quantity the ground and mixed 5min in mortar are weighed, is added after mixing
HPMC and citric acid grind 5min, are eventually adding after magnesium stearate grinding 2min under conditions of rotating speed 12.0rpm, pressure " 3 "
Carry out tabletting.
(3) HPLC methods measure release rate of vitamin C preparation：
Chromatograph：Agilent 1260；Chromatographic column：Diamonsil C18(2)5u 250×4.6mm；
Mobile phase：0.02mol/L potassium phosphate buffers (phosphoric acid tune pH 3.0)：Methanol=95：5；
Flow velocity：1mL/min；Column temperature：25℃；Sample size：20μL；Detection wavelength：245nm；
Drug release determination device：Chinese Pharmacopoeia the 4th 0,931 second method (paddle method) of version in 2015；
Leaching condition：Dissolution medium is 1000mL water, rotating speed 100rpm, 37 DEG C of temperature；
Sample point：5mL is sampled in 0.5,1,2,4,6,8,10 and 12h, and equality of temperature same volume fluid infusion, sample solution cross 0.45
μm miillpore filter, filtrate are measured with HPLC.
Release result such as Fig. 6.
(4) vitamin C sustained release tablets accelerated stability is tested
By vitamin C sustained release tablets temperature be 40 DEG C, humidity be 75% stability experiment case in carry out accelerated stability
Experiment is investigated, and under the conditions of the different acceleration time, the similitude f2 values of vitamin C sustained release tablets release profiles are all more than 50, content without
Notable difference.Vitamin C sustained release tablets in the utility model have good stability.
6 vitamin C sustained release tablets of table accelerate sample size to measure
Stability result such as Fig. 7.
The preparation of 4 vitamin C sustained release tablets of implementation column
(1) formula of vitamin C sustained release tablets is as follows：
The formula of 7 vitamin C sustained release tablets of table
| Ingredient | Every dosage (mg) | Percentage (%) |
| VC (60 mesh) | 100.0 | 55.6 |
| HPMC(K100M) | 39.3 | 21.8 |
| Chitosan | 36.0 | 20.0 |
| Citric acid | 2.0 | 1.1 |
| Magnesium stearate | 1.8 | 1.0 |
| Superfine silica gel powder | 0.9 | 0.5 |
| Piece weight | 180 | / |
(2) preparation method：Formulation and technology is the same as embodiment 3.
(3) HPLC methods measure release rate of vitamin C preparation：With implementation column 3.
Release result such as Fig. 8.
(4) vitamin C sustained release tablets accelerated stability is tested
By vitamin C sustained release tablets temperature be 40 DEG C, humidity be 75% stability experiment case in carry out accelerated stability
Experiment is investigated, and under the conditions of the different acceleration time, the similitude f2 values of vitamin C sustained release tablets release profiles are all more than 50, content without
Notable difference.Vitamin C sustained release tablets in the utility model have good stability.
8 vitamin C sustained release tablets of table accelerate sample size to measure
| Acceleration time | Content/mg |
| Do not accelerate | 96.0 |
| Accelerate 1 month | 94.4 |
| Accelerate 2 months | 95.9 |
| Accelerate 3 months | 98.5 |
| Accelerate 6 months | 95.4 |
The preparation of 5 mcg vitamin sustained release tablets of embodiment
(1) formula of mcg vitamin sustained release tablets is as follows：
The formula of 9 mcg vitamin sustained release tablets of table
| Supplementary material title | Content (mg)/piece | Percentage/% |
| Vitamin A powder (325000IU) | 4.6 | 2.56 |
| Folic acid (VB9) | 0.4 | 0.22 |
| Natural VE acetate powder (50%) | 32.0 | 17.78 |
| Vitamin d3 powder (100000IU/g) (2.5 ‰) | 5.2 | 2.89 |
| Vitamin B12 (0.1%) | 3.2 | 1.78 |
| Biotin (2%) | 2.25 | 1.25 |
| Carboxyrnethyl starch sodium | 9.0 | 5.00 |
| Lactose (vertical compression type) | 30.6 | 17.00 |
| Silica | 1.8 | 1.00 |
| Magnesium stearate | 1.8 | 1.00 |
| Microcrystalline cellulose (vertical compression type, MCC) | 83.75 | 46.53 |
| Coating powder | 5.4 | 3.00 |
| Total amount | 180 | 100 |
(2) preparation method：
Supplementary material pre-treatment：Supplementary material crosses 60 mesh sieve；
It is uniformly mixed：Each supplementary material is crossed into 60 mesh sieve, is uniformly mixed, it is spare.It is eventually adding the magnesium stearate of recipe quantity, is mixed
Close uniform, tabletting.
Mixing：Vitamin A powder, vitamin D powder, vitamin E powder, VB7, VB9 and VB12 premix；Other auxiliary materials are added；Add
Enter magnesium stearate mixing.
Tabletting parameter：Diameter 6mm, piece weight 175-185mg.
(3) Detection of Stability
Detection of Stability method is the same as embodiment 3.VB9 stability results are shown in Fig. 9.
Test result is shown, in mcg vitamin piece, VB9 ingredients are stablized relatively, so VB9 is suitble to that mcg vitamin is added
In piece.
The preparation of 6 multi-vitamins sustained release tablets capsule of embodiment
Vitamin C sustained release tablets and embodiment 5 made from B family vitamin sustained release tablets made from embodiment 1, embodiment 3 are made
The mcg vitamin sustained release tablets obtained are packed by Figure 10 in capsule shells, obtain multi-vitamins sustained release tablets capsule.
The preparation of 7 multi-vitamins sustained release tablets capsule of embodiment
Vitamin C sustained release tablets and embodiment 5 made from B family vitamin sustained release tablets made from embodiment 2, embodiment 4 are made
The mcg vitamin sustained release tablets obtained are packed by Figure 10 in capsule shells, obtain multi-vitamins sustained release tablets capsule.
The above is only the preferred embodiment of the utility model, it is noted that for the common skill of the art
For art personnel, without departing from the principle of this utility model, several improvements and modifications can also be made, these improve and
Retouching also should be regarded as the scope of protection of the utility model.
Claims (8)
1. a kind of multivitamin tablet capsule, which is characterized in that including the multivitamin tablet in capsule and capsule, the capsule
Including capsule body (1) and capsule cap (2), the multivitamin tablet in the capsule includes B family vitamin piece (3), VITAMIN C TABLET
(4) and mcg vitamin piece (5), the B family vitamin piece (3), the VITAMIN C TABLET (4) and the mcg vitamin piece (5)
Random alignment.
2. multivitamin tablet capsule according to claim 1, which is characterized in that the multivitamin tablet is that coating is multiple
Close multivitamin.
3. multivitamin tablet capsule according to claim 1, which is characterized in that the shape of the multivitamin tablet is
Cylinder, sphere or multi-face solid structure.
4. multivitamin tablet capsule according to claim 1, which is characterized in that in the multivitamin tablet capsule
It is filled by auxiliary material in gap.
5. multivitamin tablet capsule according to claim 4, which is characterized in that the auxiliary material is hydroxypropyl methylcellulose
Element, microcrystalline cellulose, maltodextrin, pregelatinized starch, isomalt, starch or dextrin.
6. multivitamin tablet capsule according to claim 1, which is characterized in that the B family vitamin piece is the dimension life of B races
Plain sustained release tablets.
7. multivitamin tablet capsule according to claim 1, which is characterized in that the VITAMIN C TABLET is slow for vitamin C
Release piece.
8. multivitamin tablet capsule according to any one of claim 1 to 7, which is characterized in that the type of the capsule
Number for one kind in 0 to No. 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201621459935.7U CN207912919U (en) | 2016-12-28 | 2016-12-28 | A kind of multivitamin tablet capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201621459935.7U CN207912919U (en) | 2016-12-28 | 2016-12-28 | A kind of multivitamin tablet capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN207912919U true CN207912919U (en) | 2018-09-28 |
Family
ID=63611434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201621459935.7U Active CN207912919U (en) | 2016-12-28 | 2016-12-28 | A kind of multivitamin tablet capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN207912919U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110420189A (en) * | 2019-08-27 | 2019-11-08 | 新乡市常乐制药有限责任公司 | A kind of control method that vitamin C tablet is anti-oxidation |
-
2016
- 2016-12-28 CN CN201621459935.7U patent/CN207912919U/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110420189A (en) * | 2019-08-27 | 2019-11-08 | 新乡市常乐制药有限责任公司 | A kind of control method that vitamin C tablet is anti-oxidation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106692096B (en) | A kind of multi-vitamins sustained release tablets capsule | |
| CN106038473A (en) | Compositions and methods for the sustained release of beta-alanine | |
| CN109223725A (en) | For with the pharmaceutical composition containing dimethyl fumarate of low daily dose application | |
| CN101375849B (en) | Novel dosage form of sinomenine medicament or hydrochlorate thereof and preparation technique thereof | |
| CN103458900A (en) | Stable compositions of tetrahydrobiopterin | |
| CN101695575A (en) | Pharmaceutical composition containing statin-type lipid-lowering medicaments, phenformin-type hypoglycemic medicaments and nicotinic acid | |
| CN101129351A (en) | Iron supplement composition, its preparing method and application of the same | |
| CN106165905B (en) | A kind of calcium adds vitamine soft capsule and preparation method | |
| KR20050047130A (en) | Composition comprising panax ginseng and paullinia cupana extracts | |
| CN101716132B (en) | Febuxostat enteric preparation | |
| CN207912919U (en) | A kind of multivitamin tablet capsule | |
| TWI404546B (en) | Coating composition | |
| CN104434826B (en) | A kind of Rosuvastatin calcium dispersible tablet | |
| CN107982241B (en) | Potassium sodium dehydroandroan drographolide succinate enteric preparation and preparation method thereof | |
| CN101990427A (en) | Combination of mitiglinide and metformin and process for preparing same | |
| CN102441019A (en) | Chinese medicinal chrysanthemum buccal tablet | |
| CN106822097A (en) | A kind of pharmaceutical composition containing orlistat for losing weight | |
| CN102058878B (en) | Prosoma pellet tablet for generating allicin in stomach and preparation method thereof | |
| CN101278935A (en) | Medical composition containing derivative of vitamin B group | |
| CN103655574A (en) | Compound ferrous succinate and folic acid composition | |
| CN101590051B (en) | Drug combination containing nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor | |
| US10894059B2 (en) | NADH compound composition, and preparation and use thereof | |
| CN104524139B (en) | Allium wallichii extract and application thereof | |
| CN106420940A (en) | Compound double-blossom effervescent tablet, preparing method and quality control method | |
| CN104840480B (en) | Metformin/folic acid/vitamin B12New application of pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |